Peritoneal Metastases From Prostate Carcinoma Treated With 177Lu-PSMA-I&T

alexandrossfakianakis shared this article with you from Inoreader Peritoneal Metastases From Prostate Carcinoma Treated With 177Lu-PSMA-I&T via Clinical Nuclear Medicine - Published Ahead-of-Print A 71-year-old man was referred for 177Lu-PSMA therapy. He had metastatic castration-resistant prostate cancer, progressive on several treatment lines, with current PSA 260 μg/L and deteriorating condition. CT showed ascites with omental and peritoneal metastases, all positive on PSMA PET/CT. He was treated with 4 cycles of 7.4 GBq (0.2 Ci) 177Lu-PSMA-I&T. Posttherapy scans showed good targeting of all metastases. After 4 cycles, PSA had dropped to 44 μ/L. Four months after the fourth cycle, the patients' general condition had significantly improved, and PSA had decreased to 7.0 μg/L. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.